Evaluation of [11C] N-methyl lansoprazole as a radiopharmaceutical for PET imaging of tau neurofibrillary tangles

ACS Medicinal Chemistry Letters

Volumn 3, Issue 11, 2012, Pages 936-941

  Shao, Xia ^a   Carpenter, Garrett M ^a   Desmond, Timothy J ^a   Sherman, Phillip ^a   Quesada, Carole A ^a   Fawaz, Maria ^a   Brooks, Allen F ^a   Kilbourn, Michael R ^a   Albin, Roger L ^a,b   Frey, Kirk A ^a   Scott, Peter J H ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VAAAHS   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Alzheimer's disease; carbon 11; neuroimaging; positron emission tomography imaging; tauopathies

Indexed keywords

CYCLOSPORIN A; MULTIDRUG RESISTANCE PROTEIN 1; N METHYL LANSOPRAZOLE C 11; RADIOPHARMACEUTICAL AGENT; TAU PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN CORTEX; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG PURITY; DRUG SCREENING; DRUG SYNTHESIS; DRUG UPTAKE; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIMATE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN EXPRESSION; RADIOCHEMISTRY; RAT; RELATIVE DENSITY; TRANSGENIC RAT; WILD TYPE;

PRIMATES; RATTUS; RODENTIA;

EID: 84868683533     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml300216t     Document Type: Article

References (35)

1. Plassman, B. L.; Langa, K. M.; Fisher, G. G.; Heeringa, S. G.; Weir, D. R.; Ofstedal, M. B.; Burke, J. R.; Hurd, M. D.; Potter, G. G.; Rogers, W. L.; Steffens, D. C.; Willis, R. J.; Wallace, R. B. Prevalence of dementia in the United States: the aging, demographics, and memory study Neuroepidemiology 2007, 29, 125-132
2. Perl, D. P. Neuropathology of Alzheimer's disease Mt. Sinai J. Med. 2010, 77, 32-42
3. Francis, P. T.; Palmer, A. M.; Snape, M.; Wilcock, G. K. The cholinergic hypothesis in Alzheimer's disease: A review of progress J. Neurol. Neurosurg. Psychiatry 1999, 66, 137-147
4. For a review see Zeman, M. N.; Carpenter, G. M.; Scott, P. J. H. Diagnosis of dementia using nuclear medicine imaging modalities. In 12 Chapters on Nuclear Medicine; Gholamrezanezhad, A., Ed.; In Tech: Croatia, 2011; pp 199-230.
5. Morais, G. R.; Paulo, A.; Santos, I. A synthetic overview of radiolabeled compounds for β-amyloid imaging Eur. J. Org. Chem. 2012, 1279-1293
6. Nordberg, A. PET Imaging of amyloid in Alzheimer's disease Lancet Neurol. 2004, 3, 519-527
7. Nordberg, A. Amyloid imaging in Alzheimer's disease Neuropsychologia 2008, 46, 1636-1641
8. Herholz, K.; Ebmeier, K. Clinical amyloid imaging in Alzheimer's disease Lancet Neurol. 2011, 10, 667-670
9. Karran, E.; Mercken, M.; De Strooper, B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics Nat. Rev. Drug Discovery 2011, 10, 698-712
10. Hardy, J.; Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics Science 2002, 297, 353-356
11. Klunk, W. E.; Engler, H.; Nordberg, A.; Wang, Y.; Blomqvist, G.; Holt, D. P.; Bergström, M.; Savitcheva, I.; Huang, G. F.; Estrada, S.; Ausén, B.; Debnath, M. L.; Barletta, J.; Price, J. C.; Sandell, J.; Lopresti, B. J.; Wall, A.; Koivisto, P.; Antoni, G.; Mathis, C. A.; Långstrom, B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B Ann. Neurol. 2004, 55, 306-319
12. Vandenberghe, R.; Van Laere, K.; Ivanoiu, A.; Salmon, E.; Bastin, C.; Triau, E.; Hasselbalch, S.; Law, I.; Andersen, A.; Korner, A.; Minthon, L.; Garraux, G.; Nelissen, N.; Bormans, G.; Buckley, C.; Owenius, R.; Thurfjell, L.; Farrar, G.; Brooks, D. J. 18F-Flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial Ann. Neurol. 2010, 68, 319-329
13. 18F-AV-45 (Florbetapir F 18) J. Nucl. Med. 2010, 51, 913-920
14. 18F-BAY94-9172, a novel PET tracer: proof of mechanism Lancet Neurol. 2008, 7, 129-135
15. Rowe, C. C.; Villemagne, V. L. Brain amyloid imaging J. Nucl. Med. 2011, 52, 1733-1740
16. Clark, C. M.; Schneider, J. A.; Bedell, B. J.; Beach, T. G.; Bilker, W. B.; Mintun, M. A.; Pontecorvo, M. J.; Hefti, F.; Carpenter, A. P.; Fllitter, M. L.; Krautkramer, M. J.; Kung, H. F.; Coleman, R. E.; Doraiswamy, P. M.; Fleisher, A. S.; Sabbagh, M. N.; Sadowsky, C. H.; Reiman, E. M.; Zehntner, S. P.; Skovronsky, D. M. for the AV45-A07 Study Group. Use of florbetapir-PET for imaging β-amyloid pathology J. Am. Med. Assoc. 2011, 305, 275-283
17. Wolk, D. A.; Grachev, I. D.; Buckley, C.; Kazi, H.; Grady, M. S.; Trojanowski, J. Q.; Hamilton, R. H.; Sherwin, P.; McLain, R.; Arnold, S. E. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology Arch. Neurol. 2011, 68, 1398-1403
18. Giannakopoulos, P.; Herrmann, F. R.; Bussière, T.; Bouras, C.; Kövari, E.; Perl, D. P.; Morrison, J. H.; Gold, G.; Hof, P. R. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease Neurology 2003, 60, 1495-1500
19. Ludolph, A. C.; Kassubek, J.; Landwehrmeyer, B. G.; Mandelkow, E.; Mandelkow, E.-M.; Burn, D. J.; Caparros-Lefebvre, D.; Frey, K. A.; de Yebenes, J. G.; Gasser, T.; Heutink, P.; Höglinger, G.; Jamrozik, Z.; Jellinger, K. A.; Kazantsev, A.; Kretzschmar, H.; Lang, A. E.; Litvan, I.; Lucas, J. J.; McGeer, P. L.; Melquist, S.; Oertel, W.; Otto, M.; Paaviour, D.; Reum, T.; Saint-Raymond, A.; Steele, J. C.; Tolnay, M.; Tumani, H.; van Swieten, J. C.; Vanier, M. T.; Vonsattel, J.-P.; Wagner, S.; Wszolek, Z. K. for the Reisensburg Working Group for Tauopathies with Parkinsonism. Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options Eur. J. Neurol. 2009, 16, 297-309
20. Okamura, N.; Suemoto, T.; Furumoto, S.; Suzuki, M.; Shimadzu, H.; Akatsu, H.; Yamamoto, T.; Fujiwara, H.; Nemoto, M.; Maruyama, M.; Arai, H.; Yanai, K.; Sawada, T.; Kudo, Y. Quinoline and benzimidazole derivatives: Candidate probes for in vivo imaging of tau pathology in Alzheimer's disease J. Neurosci. 2005, 25, 10857-10862
21. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease Brain 2011, 134, 1089-1100
22. Villemagne, V. L.; Furumoto, S.; Fodero-Tavoletti, M. T.; Mulligan, R. S.; Hodges, J.; Kudo, Y.; Masters, C. L.; Yanai, K.; Rowe, C. C.; Okamura, N. In vivo tau imaging in Alzheimer's disease J. Nucl. Med. 2012, 53 (Suppl. 1) 11P
23. Zhang, W.; Arteaga, J.; Cashion, D. K.; Chen, G.; Gangadharmath, U.; Gomez, L. F.; Kasi, D.; Lam, C.; Liang, Q.; Liu, C.; Mocharla, V. P.; Mu, F.; Sinha, A.; Szardenings, A. K.; Wang, E.; Walsh, J. C.; Xia, C.; Yu, C.; Zhao, T.; Kolb, H. C. A Highly Selective and Specific PET Tracer for Imaging of Tau Pathologies J. Alzheimers Dis. 2012, 31, 601-612
24. Small, G. W.; Kepe, V.; Ercoli, L. M.; Siddarth, P.; Bookheimer, S. Y.; Miller, K. J.; Lavretsky, H.; Burggren, A. C.; Cole, G. M.; Vinters, H. V.; Thompson, P. M.; Huang, S. C.; Satyamurthy, N.; Phelps, M. E.; Barrio, J. R. PET of brain amyloid and tau in mild cognitive impairment N. Engl. J. Med. 2006, 355, 2652-2663
25. Rojo, L. E.; Alzate-Morales, J.; Saavedra, I. N.; Davies, P.; Maccioni, R. B. Selective interaction of lansoprazole and astemizole with tau polymers: Potential new clinical use in diagnosis of Alzheimer's disease J. Alzheimers Dis. 2010, 19, 573-589
26. 11C]- labeled radiopharmaceuticals using a TRACERlab FXc-pro J. Labelled Compd. Radiopharm. 2011, 54, 819-838
27. +)-ATPase by Proton Pump Inhibitors J. Am. Chem. Soc. 2004, 126, 7800-7811
28. Sarkadi, B.; Homolya, L.; Szakács, G.; Váradi, A. Human multidrug resistance ABCB and ABCG transporters: Participation in a chemoimmunity defense system Physiol. Rev. 2006, 86, 1179-1236
29. 123I]R91150 in rodent brain Eur. J. Nucl. Med. Mol. Imaging 2009, 36, 446-453
30. Petrou, M.; Koeppe, R. A.; Scott, P. J. H.; Bohnen, N. I.; Kilbourn, M. R.; Frey, K. PET Imaging of the vesicular acetylcholine transporter J. Nucl. Med. 2012, 53 (Suppl. 1) 89P
31. Karol, M. D.; Machinist, J. M.; Cavanaugh, J. M. Lansoprazole pharmacokinetics in subjects with various degress of kidney function Clin. Pharmacol. Ther. 1997, 61, 450-458
32. Kim, K.-A.; Kim, M.-J.; Park, J.-Y.; Shon, J.-H.; Yoon, Y.-R.; Lee, S.-S.; Liu, K.-H.; Chun, J.-H.; Hyun, M.-H.; Shin, J.-G. Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes Drug Metab. Dispos. 2003, 31, 1227-1234
33. Pearce, R. E.; Rodrigues, A. D.; Goldstein, J. A.; Parkinson, A. Identification of the human P450 enzymes involved in lansoprazole metabolism J. Pharmacol. Exp. Ther. 1996, 277, 805-816
34. Williams, D. R.; Holton, J. L.; Strand, C.; Pittman, A.; de Silva, R.; Lees, A. J.; Revesz, T. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome Brain 2007, 130, 1566-1576
35. Anderson, J. M.; Hampton, D. W.; Patani, R.; Pryce, G.; Crowther, R. A.; Reynolds, R.; Franklin, R. J.; Giovannoni, G.; Compston, D. A.; Baker, D.; Spillantini, M. G.; Chandran, S. Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis Brain 2008, 131, 1736-1748